TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06531980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants receive usual treatment at their local Child and Family Services. This treatment, known as Treatment as Usual (TAU), is not standardized but reflects the care they would receive in regular practice. It aligns with national clinical guidelines and includes individual therapy, parental counseling, and assessments. Typically, the treatment is provided by a therapist trained in cognitive behavioral therapy (CBT) or a psychologist
Study: NCT06166628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Geniculate artery embolization
Description: Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve phenol nerve ablation
Description: A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Skin infiltration of 2cc of 0.25% bupivacaine at the knee
Description: A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
Study: NCT05527457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: 160 μg BAY2586116 nasal spray application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: 160 μg BAY2586116 nasal spray application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline) nasal spray application
Study: NCT06395844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METR-NK cell(Metabolic Remodeling Nature Killer Cells)
Description: The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
Study: NCT06504277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Pressure Penumoperitoneum
Description: Maintained Pneumoperitoneum with low pressure of 10 mm Hg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pressure Group (No intervention- active comparator)
Description: Maintained Pneumoperitoneum at standard pressure of 15 mm Hg
Study: NCT05835414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)
Description: Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.
Study: NCT04977206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutual Goal-Setting Education
Description: Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
Study: NCT05286593

Intervention type: DRUG
Group type: OTHER
Intervention: Slow Infusion of Rubidium-82
Description: Normal volunteers will receive weight based doses of Rb-82 infused as a slow infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Slow Infusion of Rubidium-82
Description: Clinical patients will receive weight based doses of Rb-82 infused as a slow infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Slow Infusion of Rubidium-82
Description: Infarct volunteers will receive weight based doses of Rb-82 infused as a slow infusion
Study: NCT04981275

Intervention type: OTHER
Intervention: No intervention study
Description: This observational study will only collect data, not provide any intervention to participants.

Intervention type: OTHER
Intervention: No intervention study
Description: This observational study will only collect data, not provide any intervention to participants.
Study: NCT06202196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk prevention session
Description: The patient will have a consultation dedicated to information on the risks with the neurologist within 1 to 3 months (during this period, the patient must complete the seizure diary).~An appointment with the psychologist within 2 weeks +/- 1 week following the risk discussion consultation will also be scheduled. In this interval of 2 weeks, the patient will have the possibility of reaching the neurologist, the psychologist or the nurse by telephone if he feels the need.~Then participants will be proposed the therapeutic education session including a workshop called Recognizing and Managing the Risks of Epilepsy. The last visit 3 months after the last session will assess differents questionnaires/scales including the Epilepsy Self Management Scale (ESMS).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Therapeutic Patient Education (TPE) management
Description: The control group will have usual follow-up including consultations with the neurologist and follow-up of the usual TPE program, namely the individual interview and follow-up of the usual TPE workshops for each center.
Study: NCT06364709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Criterion-learning practice
Description: The experiments will be presented on a computer. On each criterion-learning trial, a picture is presented and the participant is asked to try to produce the name for the object with or without a cue. Correct-answer feedback is provided. Criterion learning involves presenting a block of items in fixed order, and on each trial, the experimenter or a voice-recognition component will code the response during the trial as correct/incorrect. When the item reaches its assigned criterion level, it is dropped from further training in a session.
Study: NCT05356156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of the mesenteric defects
Description: The surgically created mesenteric defects will be closed after radical gastrectomy with D1+/D2 lymph node dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-closure of the mesenteric defects
Description: The surgically created mesenteric defects will not be closed after radical gastrectomy with D1+/D2 lymph node dissection.
Study: NCT04119271

Intervention type: OTHER
Group type: OTHER
Intervention: Breathe Easy at Home Kit Products
Description: HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
Study: NCT06646484

Intervention type: DIAGNOSTIC_TEST
Intervention: Impedancemetry evaluation
Description: Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
Study: NCT06413290

Intervention type: OTHER
Intervention: PIFP block group
Description: Ultrasound-guided PIFP block will be performed approximately 30 minutes before surgery in patients undergoing cardiac surgery

Intervention type: OTHER
Intervention: Control group
Description: No intervention
Study: NCT05215548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic thoracic surgery
Description: The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib
Description: The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
Study: NCT06272903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% benzocaine, topical anesthetic
Description: Indicated as a topical anesthetic for use on oral mucosa prior to local anesthetic injections, scaling and prophylaxis. Also useful to relieve discomfort associated with taking impressions and intra- oral radiographs.~The benzocaine topical anesthetic will be applied according to standard clinical practice, aiming to provide local anesthesia to the treatment site and minimize discomfort during the procedure (placing elastomeric orthodontic separators).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Children's Toothpaste
Description: Strawberry-flavored children's toothpaste available in Dubai, UAE.
Study: NCT05419193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Day of randomization:~propranolol IV vp for 7 days after randomization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Patients will receive usual care and drug use in hospital
Study: NCT06533436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corded tube care
Description: The caregiver cut a 6 cm strip of Tensoplast® and wrapped it around the intubation probe at the level of the prescribed fixation mark at the corner of the mouth. The cord strands are placed around the patient's head, tightened, and a double knot is tied at the patient's cheek. Compresses are placed over the ears to protect them from possible lesions caused by the cords.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tube care attached by AnchorFast
Description: Shaving is recommended for patients with beards, and prior family consent is required for patients with beards.~AnchorFast is Suitable for intubation probes from 5 to 10 mm in diameter, it adapts to different morphologies thanks to hydrocolloid dressings bonded to the face and an adjustable cord around the neck. Due to its rigidity, this device is not recommended for patients whose condition requires them to be positioned in the ventral decubitus (VD) or lateral decubitus position.

Intervention type: OTHER
Group type: OTHER
Intervention: Caregiver's evaluation on each tube fixation
Description: The caregivers who performs the interventions according to the study will fill question form to assess the worload and the confort of the tube care for each intervention type The caregivers are both a research actor and a study population. One of the secondary aims of this study is to evaluate the two types of tube-fixing with regard to caregiver workload and comfort in performing care. Caregivers will complete identical questionnaires assessing their satisfaction with the two types of tube fixation studied in arms 1 and 2.
Study: NCT06451965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timeline Intervention
Description: The proposed intervention consists of six sessions. In Session One, the focus is on building rapport, assessing individual difficulties, setting client-focused goals, and introducing the timeline. Participants complete timeline examples during the session and as homework.~In Session Two, psychoeducation is provided regarding the impact of stroke, addressing changes in identity and associated feelings of grievance.~Session Three onwards introduces active change methods, encouraging reflection on complex life events. The aim is to promote resilience, meaning, self-compassion, and self-acceptance by exploring past coping strategies and finding significance in events of regret. This framework aims to enhance research on complex interventions, considering efficacy, effectiveness, theory-based approaches, and systems perspectives.
Study: NCT05424640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 1
Description: Description in the arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 2
Description: Description in the arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 3
Description: Description in the arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber 4
Description: Description in the arm description
Study: NCT04687514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide: first week 1x 1.5mg in 0.5 ml, following 3 weeks 2 x 1.5 mg weekly in 0.5ml each, via Pen s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
Study: NCT04696211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-with-movement exercise
Description: A music-with-movement exercise programme to reduce chronic pain in older adults.
Study: NCT04525963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative visit of the operating room nurse and patient education
Description: The operating room nurse, who is given intervention training, will visit the patient before the operation. After the oral training of the operating room nurse, a printed booklet will be left for the patient to read.
Study: NCT05288062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspirate/biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspirate/biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspirate/biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspirate/biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given orally
Study: NCT04698967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purposeful Pathways
Description: Purposeful Pathways is a manualized intervention to assist veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Work Experience
Description: Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transitional Work Experience
Description: Provides Veterans with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TWE is time-limited. TWE is staffed by vocational rehabilitation specialists (VRS).
Study: NCT05039060

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modified MAC diet (3-weeks)
Description: * Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified MAC diet (3-weeks)
Description: * Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis
Study: NCT05628922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and concurrent chemoradiation
Description: Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and concurrent chemoradiation
Description: Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and concurrent chemoradiation
Description: Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles.
Study: NCT04991090

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: escalation dose of LLNs
Description: The lymph nodes (SA ≥ 5 mm) existed at the internal iliac and obturator would be delineated, named as GTVnd, and received a radiation dose boost of 58Gy.